Healthcare provider profile · identity verified

Ajay Sharan Mathur, MD

Family Practice · ANAHEIM, CA · NPI 1437220415

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	725	321
Amlodipine Besylate	Amlodipine Besylate	349	160
Rosuvastatin Calcium	Rosuvastatin Calcium	307	138
Levothyroxine Sodium	Levothyroxine Sodium	250	117
Losartan Potassium	Losartan Potassium	220	118
Lisinopril	Lisinopril	209	103
Ozempic	Semaglutide	194	37
Alendronate Sodium	Alendronate Sodium	187	79
Tamsulosin Hcl	Tamsulosin Hcl	185	75
Omeprazole	Omeprazole	182	100
Meloxicam	Meloxicam	172	101
Atenolol	Atenolol	164	75
Metformin Hcl Er	Metformin Hcl	140	69
Simvastatin	Simvastatin	138	69
Pantoprazole Sodium	Pantoprazole Sodium	132	49
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	122	60
Trazodone Hcl	Trazodone Hcl	119	41
Metformin Hcl	Metformin Hcl	118	60
Albuterol Sulfate Hfa	Albuterol Sulfate	109	89
Gabapentin	Gabapentin	105	53
Terazosin Hcl	Terazosin Hcl	103	33
Finasteride	Finasteride	102	42
Glipizide	Glipizide	102	51
Prednisone	Prednisone	88	77
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	84	46
Metoprolol Tartrate	Metoprolol Tartrate	82	37
Bisoprolol Fumarate	Bisoprolol Fumarate	81	35
Lorazepam	Lorazepam	80	19
Triamcinolone Acetonide	Triamcinolone Acetonide	76	50
Alprazolam	Alprazolam	72	27
Allopurinol	Allopurinol	69	27
Hydrochlorothiazide	Hydrochlorothiazide	67	37
Sertraline Hcl	Sertraline Hcl	67	37
Fluticasone Propionate	Fluticasone Propionate	61	21
Fluoxetine Hcl	Fluoxetine Hcl	59	25
Tramadol Hcl	Tramadol Hcl	58	28
Pradaxa	Dabigatran Etexilate Mesylate	57	24
Jardiance	Empagliflozin	56	24
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	55	16
Doxycycline Monohydrate	Doxycycline Monohydrate	54	51
Pioglitazone Hcl	Pioglitazone Hcl	53	22
Wixela Inhub	Fluticasone Propion/Salmeterol	50	24
Cephalexin	Cephalexin	49	45
Duloxetine Hcl	Duloxetine Hcl	48	24
Ezetimibe	Ezetimibe	47	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	47	22
Azithromycin	Azithromycin	42	41
Ciprofloxacin Hcl	Ciprofloxacin Hcl	42	40
Hydralazine Hcl	Hydralazine Hcl	42	20
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	40	18
Eliquis	Apixaban	40	16
Ibuprofen	Ibuprofen	40	28
Fluocinonide	Fluocinonide	39	21
Hydrocortisone	Hydrocortisone	38	22
Famotidine	Famotidine	36	20
Ondansetron Odt	Ondansetron	36	19
Clopidogrel	Clopidogrel Bisulfate	34	17
Donepezil Hcl	Donepezil Hcl	33	15
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	33	32
Escitalopram Oxalate	Escitalopram Oxalate	32	17
Furosemide	Furosemide	32	24
Glipizide Er	Glipizide	32	15
Temazepam	Temazepam	32	14
Carvedilol	Carvedilol	30	15
Mirtazapine	Mirtazapine	30	11
Propranolol Hcl	Propranolol Hcl	30	12
Fenofibrate	Fenofibrate	29	suppressed
Lovastatin	Lovastatin	29	11
Potassium Chloride	Potassium Chloride	28	22
Memantine Hcl	Memantine Hcl	27	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	27	11
Azelastine Hcl	Azelastine Hcl	26	12
Humulin N	Insulin Nph Human Isophane	26	15
Terbinafine Hcl	Terbinafine Hcl	26	15
Amoxicillin	Amoxicillin	25	22
Clonazepam	Clonazepam	25	suppressed
Naproxen	Naproxen	25	11
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	24	23
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	24	20
Estradiol	Estradiol	23	13
Testosterone	Testosterone	23	suppressed
Pravastatin Sodium	Pravastatin Sodium	22	17
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	22	11
Spiriva Respimat	Tiotropium Bromide	21	suppressed
Acarbose	Acarbose	20	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	20	12
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	19
Glipizide-Metformin	Glipizide/Metformin Hcl	19	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	19	12
Cefadroxil	Cefadroxil	18	18
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Cefuroxime	Cefuroxime Axetil	17	16
Midodrine Hcl	Midodrine Hcl	17	suppressed
Warfarin Sodium	Warfarin Sodium	17	suppressed
Acyclovir	Acyclovir	16	suppressed
Morphine Sulfate Er	Morphine Sulfate	16	suppressed
Mupirocin	Mupirocin	16	15
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	16	16
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	15	suppressed
Erythromycin	Erythromycin Base	15	suppressed
Lactulose	Lactulose	15	suppressed
Colchicine	Colchicine	14	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	13	13
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Humulin R	Insulin Regular, Human	12	suppressed
Methenamine Hippurate	Methenamine Hippurate	12	suppressed
Montelukast Sodium	Montelukast Sodium	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error